Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained?
<h3>Background</h3><p dir="ltr">No previous study assessed the outcomes of sleeve gastrectomy (SG) beyond 5 years among adult patients with type 2 diabetes (T2DM). We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.</p><h3>Methods</h3>&...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <h3>Background</h3><p dir="ltr">No previous study assessed the outcomes of sleeve gastrectomy (SG) beyond 5 years among adult patients with type 2 diabetes (T2DM). We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.</p><h3>Methods</h3><p dir="ltr">This is a retrospective study of 361 consecutive T2DM patients who underwent SG at our institution (April 2011–December 2015). Postoperative data were compared to baseline and to previous time points using paired t tests. Diabetes status was also assessed at each time point.</p><h3>Results</h3><p dir="ltr">The sample consisted of 65.37% females. The mean preoperative age was 44.38 ± 9.50 years and body mass index (BMI) was 43.81 ± 6.98 kg/m<sup>2</sup>. Generally, most improvements occurred in the first year and were sustained on the long term. Postoperatively, there was a significant and sustained weight reduction, amounting to a mean decrease of 9 kg/m<sup>2</sup> in BMI at year 9 and associated excess weight loss between 59%<sub>year</sub> 1 and 46%<sub>year</sub> 9. Fasting blood glucose decreased significantly across the five time points, from 9.27 ± 4.11preop to 7.06 ± 2.70 <sub>year9 </sub>mmol/L. Mean HbA1c significantly decreased from 8.1%preop to 6.77%<sub>year 9</sub>. The prevalence of complete remission of T2DM was 20.45%, 19.44%, and 20% at 5, 7, and 9 years respectively, with significant reductions in percentages of patients using diabetes medications or insulin. Between 10% and 23% of patients experienced relapse of T2DM by 5–9 years. In comparison to baseline levels, mean blood pressure, triglycerides, high-density lipoprotein, low-density lipoprotein, total cholesterol, and hepatic enzymes levels all showed improvement in the long term.</p><h3>Conclusion</h3><p dir="ltr">Patients with T2DM experienced substantial improvements in most anthropometric and cardiometabolic outcomes within the first year, and these were sustained in the long term.</p><h2>Other Information</h2><p dir="ltr">Published in: Obesity Surgery<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s11695-024-07664-w" target="_blank">https://dx.doi.org/10.1007/s11695-024-07664-w</a></p> |
|---|